Denali expects $30M-$32M Q4 AVLAYAH net product revenue as Sanfilippo BLA filing remains planned for 2027

Seeking Alpha · November 4, 2026, 02:46 UTC

Tickers: $DNLI

Topics: biotechnology product sales revenue guidance

Read the full article at Seeking Alpha

Part of the story Denali expects $30M-$32M Q4 AVLAYAH net product revenue as Sanfilippo BLA filing remains planned for 2027 (2 articles)

More World news

CMS Announces Final Valuations and Reimbursement Rates for New ESD CPT Codes PR Newswire · November 12, 2026, 19:43 UTC
IRS Announces 2027 Retirement Contribution Limits and Social Security COLA Increase Motley Fool · November 12, 2026, 19:37 UTC
Yesway Reaffirms 2026 EBITDA Guidance and Outlines Texas Allsup’s Conversion Timeline Seeking Alpha · November 12, 2026, 19:40 UTC
Boost Run Reports 496% Year-Over-Year Revenue Growth in Q3 2026 Seeking Alpha · November 12, 2026, 19:40 UTC
AiPrise Launches Token Sharing Infrastructure to Streamline Compliance Verification PR Newswire · November 12, 2026, 19:39 UTC
Barclays Upgrades Steel Producers Cleveland-Cliffs and Reliance Amid Market Selloff Seeking Alpha · November 12, 2026, 19:32 UTC
Mercantile Bank Announces New Full-Service Banking Center in Holland, Michigan PR Newswire · November 12, 2026, 19:28 UTC
Broadwind Reports 48% Revenue Growth and Record Industrial Solutions Backlog in Q3 2026 Motley Fool · November 12, 2026, 19:25 UTC
MediWound Reports Q3 2026 Financial Results Amid Clinical Trial Expansion Motley Fool · November 12, 2026, 19:25 UTC
Twist Bioscience Reports Q4 2026 Revenue Growth and First Positive Adjusted EBITDA Motley Fool · November 12, 2026, 19:25 UTC